Lion Point Capital LP 13D and 13G filings for Marinus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:18 pm Sale |
2023-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Lion Point Capital LP | 2,134,337 3.900% |
-2,645,311 (-55.35%) |
Filing |
| 2023-02-14 4:15 pm Purchase |
2022-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Lion Point Capital LP | 4,779,648 9.900% |
1,150,026 (+31.68%) |
Filing |
| 2022-02-14 4:31 pm Sale |
2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Lion Point Capital LP | 3,629,622 9.870% |
-939,312 (-20.56%) |
Filing |
| 2021-02-12 3:55 pm Purchase |
2020-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Lion Point Capital LP | 4,568,934 12.200% |
2,975,249 (+186.69%) |
Filing |